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Abstract
Mer tyrosine kinase is ectopically expressed in acute lymphoblastic leukemia and associated with enhanced
chemoresistance and disease progression. While such effects are generally ascribed to increased engagement of oncogenic
pathways downstream of Mer stimulation by its ligand, Gas6, Mer has not been characterized beyond the scope of its
signaling activity. The present study explores Mer behavior following prolonged exposure to Gas6, a context similar to the
Gas6-enriched microenvironment of the bone marrow, where a steady supply of ligand facilitates continuous engagement
of Mer and likely sustains the presence of leukemic cells. Long-term Gas6 exposure induced production of a partially N-
glycosylated form of Mer from newly synthesized stores of protein. Preferential expression of the partial Mer glycoform was
associated with diminished levels of Mer on the cell surface and altered Mer localization within the nuclear-soluble and
chromatin-bound fractions. The presence of Mer in the nucleus is a novel finding for this receptor, and the glycoform-
specific preferences observed in each nuclear compartment suggest that glycosylation may influence Mer function within
particular subcellular locales. Previous studies have established Mer as an attractive cancer biologic target, and
understanding the complexity of its activity has important implications for potential strategies of Mer inhibition in leukemia
therapy. Our results identify several novel features of Mer that expand the breadth of its functions and impact the
development of therapeutic modalities designed to target Mer.
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Introduction
The Mer receptor tyrosine kinase (RTK)—also known as
MerTK, Nyk, and Tyro12—mediates a spectrum of physiological
functions, including platelet aggregation, macrophage clearance of
apoptotic cells, cytokine release, and cell proliferation and survival
[1]. Many of the intracellular signaling events that influence these
functions occur downstream of Mer activation upon engagement
with its ligand, Gas6. This vitamin K-dependent molecule also
serves as the common ligand for Axl and Tyro3 [2], two other
transmembrane receptors sharing homology with Mer in the
extracellular regions and a conserved sequence within the tyrosine
kinase domain. Collectively, these three proteins compose the
TAM subfamily of RTKs [1].
While their normal expression is critical in maintaining cell
function, aberrant levels of TAM receptors and their ligands have
been reported in numerous cancers and are often associated with
poor prognostic indicators [1,3,4]. Mer is ectopically expressed in
acute lymphoblastic leukemia (ALL), the most common pediatric
malignancy, both within subsets of B- and T-ALL [5,6]. Mer
promotes oncogenesis in lymphocytes—which normally do not
express Mer [5,7]—and confers resistance to chemotherapy-induced
apoptosis in leukemia and other cancer types [8,9]. Furthermore,
shRNA-mediated Mer inhibition delays disease onset and improves
drug response in a murine xenograft model of leukemia [10].
TheoncogeniceffectsassociatedwithMerarelargelyattributedto
the increased activation of pro-survival and proliferative pathways
observed in response to Mer stimulation, including those driven by
MAPK/Erk and PI3K/Akt [1,2,8,11]. Engagement of downstream
signaling pathways, which occurs transiently in vitro, is also believed
to persist in vivo due to the presence of Gas6 in the plasma [12–16]
and bone marrow [17–19]. However, such signaling events—
currently regarded as the primary mechanisms underlying the
oncogenicity of Mer—have only been defined by short-term (i.e. 10–
60 minutes) stimulation of Mer. Beyond these signaling-focused
studies, much remains unknown about receptor behavior and the
mechanisms influencing functional consequences associated with
aberrantMerexpression.Wethususedaninvitromodelofprolonged
Gas6 exposure to study Mer within a more physiologically relevant
context similar to the perpetually Gas6-replete environment
described to exist in both pathophysiologic and normal conditions.
Our initial investigations revealed that long-term Gas6 exposure
induced preferential expression of a partial Mer glycoform
normally existing at minor levels relative to the fully glycosylated
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favored Mer glycoform displayed several features indicating that it
was not merely an ineffectual precursor to the fully glycosylated
protein. In the process of elucidating the mechanisms underlying
receptor modification, we identified a relationship between Mer
glycosylation and its subcellular localization, which led to an
unexpected observation of Mer expression within the nuclear
compartments. This is the first report to demonstrate localization
of Mer—or any of the TAM receptors—in the nucleus. Not only
does this novel finding expand our understanding of Mer as a cell
surface receptor to that of a potential gene expression regulator,
but it also broadens the realm of available methods of inhibition in
the ongoing search for targeted therapies against leukemia.
Results
Prolonged Gas6 exposure induces a smaller molecular
weight form of Mer
Three human ALL cell lines—697 (B-ALL), Jurkat (T-ALL),
and HPB-ALL (T-ALL)—were used in our investigations. Cells
were cultured in the presence of 200 nM Gas6, a concentration
sufficient for Mer activation [8,20], and collected after 18 hours.
Total protein from whole-cell lysates was separated by SDS-PAGE
and Mer was detected by western blotting with an antibody
specific to its extracellular domain (Figure 1A). While the majority
of Mer from control samples existed as a 180-kDa band, Gas6-
treated cells predominantly expressed a form of Mer with a faster
electrophoretic mobility and approximate molecular weight of
150 kDa. All three ALL lines expressed this smaller molecular
weight form of Mer following prolonged Gas6 exposure, indicating
that this was not a cell line-specific effect.
Gas6 favors expression of a partial Mer glycoform
Mer contains 14 putative N-linked glycosylation sites in its
extracellular domain [21,22]. Based on this and previous reports of
glycosylation-related differences in Mer size [5,23], we sought to
determine if this same modification accounted for the ligand-
responsive decrease in molecular weight. Indeed, removal of all N-
glycosylation abolished the shift in Mer mobility between control-
and Gas6-treated cells (Figure 1B): PNGaseF digestion of Jurkat
lysates reduced Mer from both samples to approximately 110 kDa,
the approximate predicted molecular weight of the non-glycosy-
lated protein [21].
Treatment of lysates with EndoH, an endoglycosidase that
removes only mannosylated glycans [24], reduced the Gas6-
responsive Mer glycoform (150 kDa) to a similar size as that seen
with PNGaseF (Figure 1C). In addition, the partial Mer glycoform
expressed as a minor form in control cells (150 kDa, first lane) was
also susceptible to EndoH, indicating that the N-glycans on both
partial glycoforms terminated in high mannose. In contrast, the
largest Mer glycoform (180 kDa) predominating in control cells
displayed minimal sensitivity to EndoH, a characteristic common-
ly observed in proteins containing more complex N-glycan
modifications [25].
Expression of the partial Mer glycoform occurs in a time-
and Gas6-dependent manner
We next aimed to characterize the processes underlying Gas6-
favored expression of the partial Mer glycoform. Western blot
analysis revealed that enhanced expression of the partial glycoform
developed within 2 hours of Gas6 exposure and progressed into
the major form by 18 hours (Figure 2A). 200 nM Gas6 was
sufficient to produce this change in glycoform preference under
both serum-deprived and -complete conditions (Figure S1A), and a
single dose of Gas6 sustained expression of the partial glycoform
for at least 96 hours (Figure S1B). However, after inducing partial
glycoform expression with a 24-hour exposure to 200 nM Gas6,
subsequent reduction of Gas6 concentration to 100 nM restored
expression of the full glycoform within 24 hours (Figure 2B).
These findings indicated that selective replacement of fully
glycosylated Mer with the partial glycoform, likely a consequence
of continued receptor engagement, required a minimum Gas6
concentration. The dose-dependent nature of this behavior is
consistent with a requirement for kinase activation, as 100 nM
Gas6 is not sufficient to activate Mer in vitro. However, prolonged
exposure to 200 nM Gas6 still favored production of the partial
glycoform in cells expressing a kinase-dead form of Mer (Figure
S2). Additionally, we found that H2O2—which also activates Mer
in a similar, dose-dependent fashion as Gas6 [26]—did not alter
glycoform expression preference upon long-term exposure (data
not shown), further suggesting that this process is mediated by
kinase-independent mechanisms.
The Gas6-favored Mer glycoform is produced from newly
synthesized protein
To further elucidate the molecular basis of this process, we
sought to determine whether the Gas6-responsive Mer glycoform
resulted from a preexisting, partially deglycosylated protein or
from de novo partial glycosylation of a newly synthesized protein.
Cells were treated with tunicamycin (TM)—a naturally occurring
antibiotic that inhibits core glycan synthesis and thus completely
blocks glycosylation of all newly translated proteins [27]—prior to
adding Gas6. If the Gas6-responsive glycoform resulted from
partial deglycosylation of a pre-existing protein, TM would have
no effect; conversely, if the partial Mer glycoform arose from
Figure 1. Long-term exposure to Gas6 induces expression of a
partially N-glycosylated form of Mer. Whole-cell lysates were
collected from human leukemia cell lines cultured in the presence of
200 nM Gas6 (+) or vehicle control (2) for 18 hours and Mer expression
was determined by western blot. Blots were also probed with an anti-
Tubulin antibody to confirm similar loading. (A) In human ALL cell lines,
Gas6-treated cells express a major form of Mer with a faster
electrophoretic mobility (,150 kDa) than Mer in control-treated cells
(,180 kDa). (B) Jurkat cell lysates were digested with PNGaseF or
incubated under the same conditions without PNGaseF (enzyme
control) prior to SDS-PAGE. (C) Jurkat cell lysates were digested with
EndoH or enzyme control prior to SDS-PAGE. The non-glycosylated (%),
partially glycosylated (%), and fully glycosylated (%) Mer glycoforms
are indicated between panels B and C.
doi:10.1371/journal.pone.0031635.g001
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process and prevent its favored production in the presence of
Gas6. In both Gas6- and control-treated cells, TM prevented
formation of the partial glycoform (Figure 2C), a feature observed
within 5 hours of Gas6 exposure. After 24 hours, all TM-treated
cells predominantly expressed the 110-kDa, non-glycosylated form
of Mer. These results demonstrate that addition of core glycans to
newly synthesized proteins—rather than partial deglycosylation of
preexisting proteins—was the critical mechanism required for
formation of the partial glycoform.
Predominant expression of the partial Mer glycoform is
associated with altered downstream signaling
Previous in vitro studies have shown that Mer stimulation results
in increased Erk phosphorylation, with peak activation occurring
within 10 minutes of Gas6 exposure [2,11], thus establishing it
as a useful downstream readout of Mer activation. To investigate
how favored expression of the partial Mer glycoform affected
downstream signaling, Erk phosphorylation (p-Erk1/2) was
evaluated in cells predominantly expressing the full (Figure 3A)
versus partial (Figure 3B) Mer glycoform. After an initial exposure
to 200 nM Gas6 or control for either 1 or 24 hours (Gas6 #1),
Jurkat cells were exposed to a second dose of the same treatments
directly spiked in for 10 minutes (Gas6 #2), and then lysed for
western blot analysis. Following the initial 1-hour exposure to
vehicle control or 200 nM Gas6, cells treated with vehicle only
during the second exposure displayed low levels of p-Erk1/2 (lanes
1 and 2), indicating that the ligand-responsive increase in Erk
phosphorylation—observed 10 minutes after Gas6 treatment (lanes
3 and 4) and consistent with previous reports—occurred transient-
ly, and Erk activity was restored to basal levels within an hour of
initial Gas6 stimulation. When the majority of Mer still existed as
the full glycoform 1 hour after the first exposure, Gas6 stimulation
during the second exposure time elicited a robust Erk response in
doubly stimulated cells (lane 4, which contained a total of 400 nM
Gas6 for the second exposure) similar to that observed in singly
stimulated cells that had first been exposed to vehicle control (lane
3, which contained 200 nM Gas6 for the second exposure). In
contrast, when the majority of Mer existed as the partial glycoform
24 hours after initial Gas6 exposure, Erk phosphorylation was
diminished following a second Gas6 stimulation (lane 8) relative to
the increased Erk activity observed in cells stimulated for
10 minutes with Gas6 after first being exposed to vehicle control
for 24 hours (lane 7). These data indicate that predominant
Figure 2. Gas6 induces expression of the partial Mer glycoform in a time- and concentration-dependent manner from a newly
synthesized protein. Mer expression was detected by western blot of whole-cell lysates prepared from Jurkat cells. Blots were also probed with an
anti-Tubulin antibody to assess loading. (A) Equal densities of cells were treated with vehicle control (2) or 200 nM Gas6 (+) and lysed after the
indicated exposure times. (B) 24 hours after inducing expression of the partial Mer glycoform with 200 nM Gas6, cells were divided into two wells
and cultured in media containing 200 or 100 nM Gas6 for an additional 24 hours prior to lysis. Control-treated cells were cultured under the same
conditions. The Gas6 concentration during each of the two 24-hour intervals is indicated above the corresponding lane. (C) Cells were treated with
1 mg/ml tunicamycin (TM, +, top) or 0.1% DMSO vehicle control (2, top) for 1 hour prior to addition of 200 nM Gas6 (+, bottom) or vehicle control (2,
bottom). Cells were lysed 5 or 24 hours after Gas6 exposure.
doi:10.1371/journal.pone.0031635.g002
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with Gas6, correlates with the altered signaling patterns observed
downstream of Mer activation.
Reduced Mer surface expression results from partial
glycosylation
Among several factors potentially influencing this reduction in
Erk activation was the possibility that less Mer was available for
Gas6 engagement at the cell surface. To address this, surface
expression of Mer was measured by flow cytometry after exposing
cells to 200 nM Gas6 or vehicle control for 24 hours (Figure 3C).
Surface levels of Mer were decreased by approximately 25% in
Gas6-treated cells relative to control, suggesting that the altered
signaling observed in the presence of the partial Mer glycoform
may, at least in part, result from its reduced surface expression.
As previous studies have demonstrated that incomplete
glycosylation can impair delivery to the cell surface [28], we next
explored whether partial glycosylation alone was sufficient to limit
Mer expression on the cell surface. Treatment with Brefeldin A
(BFA), which disrupts trafficking from the endoplasmic reticulum
(ER) to the Golgi and thus prevents glycosylation beyond ER-
localized mannosylation [29], resulted in a partially glycosylated
form of Mer with a molecular weight similar to the minor
glycoform expressed in control cells (Figure 4A). BFA-restricted
partial glycosylation, as well as complete glycosylation inhibition
by tunicamycin (TM), both resulted in a similar approximate 25%
decrease in surface Mer expression observed by flow cytometry
(Figure 4B). These data suggest that reduced expression of surface
Mer was a primary effect of incomplete glycosylation and a
secondary consequence of prolonged Gas6 exposure.
Continuous Gas6 exposure alters Mer expression in the
nucleus
To determine if Gas6 influenced Mer elsewhere within the cell,
subcellular fractions were analyzed by western blot after treating
cells for 24 hours with 200 nM Gas6 or vehicle control. Sur-
prisingly, Mer displayed a distinct expression pattern within
the nuclear compartments—a subcellular localization not previ-
ously described for Mer. Relative to control, Mer expression
was enhanced in the nuclear-soluble fraction but diminished in
the chromatin-bound compartment of Gas6-treated samples
(Figure 5A), a reciprocal pattern of expression suggesting that
total levels of nuclear Mer were not markedly changed between
control- and Gas6-treated cells. Consistent with this observation,
immunofluorescent imaging substantiated the nuclear presence of
Mer, which remained relatively similar in cells exposed to Gas6 or
vehicle control (Figure 5B).
Nuclear compartments display distinct preferences for
Mer glycoforms
To investigate if altered expression of nuclear Mer directly
resulted from Gas6 exposure or was primarily due to its partially
Figure 3. The Gas6-favored Mer glycoform is associated with altered downstream signaling and reduced surface expression. Jurkat
cells were initially treated with 200 nM Gas6 (+) or control (2) for 1 hour (A) or 24 hours (B). After this first exposure (Gas6 #1), cells received a
second dose of the same treatments, spiked in for 10 minutes (Gas6 #2), and were then lysed to evaluate expression of the indicated proteins by
western blot (‘‘p-’’ represents a phosphorylated protein). Lane numbers are designated below blot images. Cells treated with vehicle only at the time
of the second exposure (lanes 1, 2 and 5, 6) displayed equally low levels of p-Erk1/2, indicating that basal levels of Erk activity had been restored since
the time of initial Gas6 stimulation. (C) Surface expression of Mer was assessed by flow cytometry of Jurkat cells exposed to 200 nM Gas6 or vehicle
control for 24 hours. Left: Representative histogram of Mer expression as a function of PE intensity (x-axis). Right: MFI (median fluorescence intensity)
values expressed as percent surface expression in Gas6-treated relative to control samples. Mean values and standard deviations (SD) derived from 5
independent experiments are shown (***p,0.0001, two-tailed unpaired t-test, 99% CI).
doi:10.1371/journal.pone.0031635.g003
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expression in the nuclear compartments of cells exposed to Gas6
or BFA. Cells were fractionated after treatment for 4 hours, a
timepoint that would allow us to examine localization of the
Gas6-responsive partial glycoform while fully glycosylated Mer
remained the predominant form. If reduced expression of Mer in
the chromatin-bound compartment were a Gas6-specific effect, we
would expect to see decreased levels of both the full and partial
glycoforms in the Gas6-treated samples but not the BFA-treated
samples. If this effect were primarily due to altered Mer
glycosylation, then expression of the partial glycoform would be
largely excluded from the chromatin-bound compartment in both
Gas6- and BFA-treated samples. Within the nuclear-soluble
compartment, control cells expressed the partial Mer glycoform
in minor proportion to the full glycoform; but in Gas6-treated
cells, the partial glycoform existed in closer proportion to the full
glycoform (Figure 6A). Similarly, BFA also resulted in nearly equal
levels of partial and full Mer glycoforms in the nuclear-soluble
fraction. In the chromatin-bound compartment, however, fully
glycosylated Mer predominated in all samples, and the partial Mer
glycoform expressed by BFA-treated cells was not detectable in
this fraction. This effect was further pronounced in cells exposed to
BFA for 24 hours (Figure 6B): by this point, the preexisting supply
of full Mer glycoform had been replaced by a majority of newly
translated protein bearing the BFA-restricted glycosylation, which
was expressed in the nuclear-soluble fraction but noticeably absent
in the chromatin-bound compartment.
Mer contains conserved nuclear localization and export
signals
In additional support of a role for nuclear Mer, sequence motif
and alignment analyses revealed that Mer contains putative
nuclear localization and export signals (NLS and NES, respec-
tively) within the juxtamembrane region of its intracellular
domain, both of which are conserved among the TAM family
members in humans and other species (Figure 7). The single
cluster of three basic amino acid residues (RKR) at positions 526–
528 in the Mer protein is classified as a conventional monopartite
NLS; this motif, which was first identified in the SV40 large T
antigen sequence [30], is often recognized and bound by importin
(karyopherin) proteins that facilitate transport into the nucleus
[22]. The nearby NES, residing at positions 572–583 in Mer, is
predicted to bind CRM1 (also known as exportin1/Xpo1), a
common export carrier protein [31], for transport out of the
nucleus.
Discussion
As previous experiments have focused on short-term character-
ization of Mer activation and functional effects associated with
Mer expression, this paper for the first time examines the direct
consequences of long-term Gas6 exposure on Mer. We used an in
vitro model of prolonged Gas6 exposure to study Mer under
conditions that more closely resemble the Gas6-replete environ-
ment that exists in the bone marrow [17–19] and plasma [12–
16]—one in which the constant interaction between Gas6 and
Mer presumably sustains downstream signaling activity and
promotes leukemic cell survival in vivo [8,19]. These studies
provide insight into several novel aspects of Mer that redefine its
function beyond the role of a signal transducer.
In human leukemia cell lines, continuous Gas6 exposure
promoted expression of a partially N-glycosylated form of Mer, a
glycoform that developed from de novo partial glycosylation of a
newly synthesized protein. Collectively, the data from the glycan
profiling and mechanistic studies suggest that persistent ligand
exposure induces a switch to preferentially express the same partial
Mer glycoform that normally exists as a minor form in the absence
of Gas6. This idea is supported by the similarities in molecular
weight and EndoH susceptibility (Figure 1C), which suggest a
shared glycan profile; additionally, the comparable response of the
partial glycoforms to tunicamycin (Figure 2C) indicates that they
both utilize the same mechanism of post-translational modification,
lending further support to this idea from a mechanistic perspective.
The data obtained from tunicamycin-mediated glycosylation
inhibition also provide novel insight into the receptor dynamics of
Mer: by distinguishing newly synthesized (and non-glycosylated)
proteins from mature receptors, we demonstrate that translation of
new Mer occurs within a few hours. Based on the minimal amount
of fully glycosylated Mer remaining after 24 hours of tunicamycin
exposure, it is also evident that the majority of pre-existing receptor
is recycled within this time frame. Although Mer dynamics still
remain largely uncharacterized, this finding has important
implications for drug design, as inhibitors with shorter half-lives
would not likely have a sustained effect on Mer activity.
While Gas6-favored expression of the partial glycoform was
associated with diminished levels of Mer on the cell surface
(Figure 3C), exposure to BFA or TM, which restrict or completely
inhibit glycosylation, respectively, demonstrated that the reduction
in surface Mer was likely due to its partially glycosylated state
rather than a direct consequence of ligand exposure (Figure 4). We
also now report expression of Mer in the nucleus, illustrated both
by immunofluorescent imaging and subcellular fractionation
experiments (Figures 5 and 6). That Mer is expressed in any of
the nuclear compartments—and as an intact, rather than cleaved,
receptor—is a novel finding for this protein, as well as one that has
not yet been reported for either of the other TAM receptors.
However, several other studies have established the presence of
Figure 4. Reduced surface expression of Mer results from
incomplete glycosylation. Jurkat cells were cultured in the presence
of 5 mg/ml Brefeldin A (BFA), 1 mg/ml TM, or 0.1% DMSO vehicle control
(2) for 24 hours. (A) Western blot detection of Mer from whole-cell
lysates. (B) Surface expression of Mer was measured by flow cytometry,
and MFIs from BFA- and TM-treated samples were normalized to control
MFI for each experiment. Mean values and SD derived from 3
independent experiments are shown (**p,0.005, 1-way repeated
measures ANOVA followed by Bonferroni post-tests).
doi:10.1371/journal.pone.0031635.g004
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epidermal growth factor receptor (EGFR) family of proteins [33],
fibroblast growth factor receptor [34–36], insulin receptor [37],
and insulin-like growth factor-1 receptor [38]. Expression of c-Met
[39] and RON [40], receptors closely related to the TAM family
[41], has also been demonstrated in the nucleus.
Figure 5. Prolonged Gas6 exposure alters Mer localization within the nuclear compartments. Jurkat cells were treated with 200 nM Gas6
(+) or vehicle control (2) for 24 hours. (A) Western blot detection of Mer following subcellular fractionation of cells. The following antibodies were
used to assess compartment specificity: GAPDH (cytoplasmic), HDAC1 (both nuclear-soluble and chromatin-bound), and Histone H3 (chromatin-
bound). (B) Following the 24-hour exposure, fixed and permeabilized cells were subjected to immunofluorescent staining and Mer expression
(yellow) was analyzed by confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar,5mm.
doi:10.1371/journal.pone.0031635.g005
Figure 6. Nuclear compartments display preferential expression of different Mer glycoforms. Jurkat cells were cultured in the presence
of 200 nM Gas6, 5 mg/ml BFA, or control (2) for the indicated times. Western blot detection of Mer in the nuclear-soluble and chromatin-bound
fractions (A) collected after a 4-hour exposure, and (B) following a 24-hour treatment with BFA or control. Blots were also probed for HDAC1 and
Histone H3 to ensure proper fractionation.
doi:10.1371/journal.pone.0031635.g006
Mer Glycosylation & Nuclear Expression in Leukemia
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31635Although the conserved nature of the NLS and NES (Figure 7)
suggest that Axl and Tyro3 may also localize to the nucleus, our
efforts presently aim to determine the mechanistic bases of Mer
translocation to the nucleus; as nuclear RTKs are associated with
various changes in biologic activity [42], we are also focused on
elucidating the functional significance of nuclear Mer expression.
Based on reports of nuclear RTK-related effects on gene
expression—including regulation by direct transactivation as well
as through complexed interactions [40,43–45]—ChIP-Seq profil-
ing experiments are currently underway to identify regions of
DNA influenced by Mer, which is present within the chromatin-
bound fraction (Figures 5 and 6).
Several studies have reported differential glycosylation of Mer
[5,21,23] but none have explored the functional effects associated
with this modification. The contrasting patterns of glycoform
expression observed within each nuclear fraction (Figure 6) suggest
that the nuclear compartments may exhibit distinct preferences for
specific Mer glycoforms. This glycoform-influenced nuclear
sublocalization indicates functional consequences of Mer glycosyl-
ation, suggesting that particular N-glycan modifications on Mer
may influence its affinity for DNA and/or partner proteins within
the nucleus. Our data also highlight that Mer does not exclusively
occupy the subcellular locales predicted by its glycosylation profile,
suggesting that such modifications do not always restrict or define
function. This idea is supported by a previous study emphasizing
how the functional maturity of a protein is not necessarily defined
by its degree of glycosylation: Krysov et al. found that despite the
mannosylated, so-called ‘‘immature’’ nature of the IgM m chain
expressed in chronic lymphocytic leukemia samples, increased
expression of this partial glycoform—which could be induced by
persistent antigen exposure—retained the same functional capa-
bilities as its fully glycosylated, ‘‘mature’’ counterpart [46].
Our observations widen the scope of potential Mer function and
supplement its once-singular role as a surface receptor. Both the
presence of Mer in the nucleus and the kinase-independent
formation of the partial glycoform suggest that the oncogenic
Figure 7. Mer contains conserved nuclear localization and export signals. Above, a diagram of Mer protein structure depicts the nuclear
localization signal (NLS) and nuclear export signal (NES) within the juxtamembrane region of its intracellular domain. Additional functional domains
are labeled accordingly (Ig, immunoglobulin; FNIII, fibronectin type III; TM, transmembrane). Below, sequence alignment highlights conservationo f
the C-extended monopartite variant NLS (blue) and the leucine-rich NES (green) among TAM receptors in both human and other species. Residue
positions are indicated above the human Mer sequence outlined in red. Motif analysis and sequence alignment were performed using ELM [22] and
Jalview software [49].
doi:10.1371/journal.pone.0031635.g007
Mer Glycosylation & Nuclear Expression in Leukemia
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31635effects of Mer may, at least in part, be mediated through
mechanisms involving its nuclear localization and not exclusively
through increased activation at the cell surface. While previous
studies have established Mer as an attractive therapeutic target in
leukemia, the current focus on developing Mer-specific inhibitors
emphasizes the importance of characterizing Mer function as
thoroughly as possible, as the ability to effectively target Mer is
limited by our understanding of its functions. The novel finding of
Mer expression in the nucleus—and especially the presence of
nuclear localization and export sequences—broadens the realm of
potential approaches to target Mer for therapeutic purposes.
Materials and Methods
Cell culture and treatments
The Jurkat, HeLa, and HEK 293 cell lines were obtained from
the American Type Culture Collection (ATCC), and HPB-ALL,
697, and NB4 cell lines from the German Collection of
Microorganisms and Cell Cultures (DSMZ). Cells were main-
tained in RPMI 1640 medium (VWR) supplemented with 10%
fetal bovine serum (FBS), 100 IU/L penicillin and 10 mg/ml
streptomycin at 37uC in a humidified atmosphere containing 5%
CO2. For experiments, cells were plated at an initial density of
1.0–1.3610
6 cells/ml in multi-well polystyrene tissue culture plates
and incubated with equal volumes of treatments prepared as 106
stock solutions in serum-free RPMI. Recombinant human Gas6
(885-GS, R&D Systems) was reconstituted to 2 mM (139 mg/ml)
immediately before adding to cells. Since Gas6 was lyophilized by
the manufacturer from a solution containing Tris, NaCl, and
Citrate, these additional components were included in preparation
of vehicle control, which contained the same concentrations
present in the volume of reconstituted Gas6. Tunicamycin (TM)
and Brefeldin A (BFA) were purchased from Sigma.
Preparation of lysates and cell fractions
After collecting cells by centrifugation, whole-cell lysates were
prepared on ice using lysis buffer (50 mM HEPES pH 7.5,
150 mM NaCl, 10 mM EDTA, 10% glycerol, and 1% Triton X-
100) supplemented with Halt Protease and Phosphatase Inhibitor
Cocktail (Pierce). Cell fractions were isolated by stepwise lysis of
cells using the Subcellular Protein Fractionation Kit (Pierce)
according to manufacturer protocol. Protein concentrations were
determined by 660 nm Protein Assay (Pierce).
Glycosidase treatment
Lysates were denatured for 10 minutes at 100uC with
Glycoprotein Denaturing Buffer and then digested with either
peptide:N-glycosidase F (PNGaseF) or endoglycosidase H (EndoH)
for 2 hours at 37uC in the appropriate buffer according to
manufacturer protocol (New England BioLabs). Lysate aliquots
incubated under the same conditions in the absence of enzymes
served as controls. Samples were subsequently prepared for
western blotting as described below.
Western blotting
Normalized amounts of total protein were denatured by boiling
in sample buffer (62 mM Tris pH 6.8, 0.7 M 2-mercaptoethanol,
10% glycerol, 2% SDS, and trace amount of bromophenol blue)
prior to resolving by Tris-Glycine SDS-PAGE (Invitrogen).
Proteins were transferred to PVDF membranes (Perkin-Elmer)
and probed with the indicated antibodies using the rapid
immunodetection method described previously [47]. Blots were
washed with TBST (Tris-buffered saline containing 0.05%
Tween-20) after primary and secondary immunoblotting steps.
Proteins were detected by enhanced chemiluminescence (Perkin-
Elmer) and imaged on film. All antibodies were diluted according
to manufacturer recommendations in TBST containing 1% (w/v)
nonfat milk. The anti-Mer antibody (#1633-1, Epitomics) was
raised against a synthetic peptide mapping between amino acids
20 and 50 of human MerTK (Swiss Prot Q12866), a region within
the extracellular domain that does not contain any putative N-
glycosylation sites, and control experiments demonstrating spec-
ificity of this antibody for Mer in immunoblotting analyses are
shown in Figure S3A. Antibodies used to detect Tubulin (#2125),
phospho-p44/42 MAPK (phospho-Erk1/2, Thr202/Tyr204,
#9106), p44/42 MAPK (Erk1/2, #9102), HDAC1 (#5356),
GAPDH (#2118), Histone H3 (#4499), and Tyro3 (#5585) were
purchased from Cell Signaling Technology; the anti-Axl antibody
(AF154) was purchased from R&D Systems and the HRP-
conjugated anti-actin antibody (sc-1616) from Santa Cruz
Biotechnology. Primary antibodies were labeled with HRP-
conjugated secondary antibodies (donkey anti-rabbit, 711-035-
152; goat anti-mouse, 115-035-062) purchased from Jackson
ImmunoResearch.
Flow cytometric analysis of surface Mer expression
10
6 cells were collected by centrifugation and kept at 4uC for the
duration of the protocol. Phosphate-buffered saline (PBS)
containing 1% FBS and 0.09% sodium azide was used for all
wash and staining steps. After two washes, cells were incubated for
30 minutes with a 1:50 dilution of Mer590, a monoclonal
antibody directed against the Mer extracellular domain produced
in a murine hybridoma as previously described [48], and washed
twice more before staining with a 1:50 dilution of phycoerythrin
(PE)-labeled anti-mouse IgG (115-116-146, Jackson ImmunoR-
esearch) for 30 minutes. Cells were washed four times and then
resuspended in cold PBS. Fluorescence was measured using a
FC500 flow cytometer with CXP data analysis software (Beckman
Coulter). Control experiments demonstrating specificity of this
antibody for Mer are shown in Figure S3C.
Immunofluorescence microscopy
Cells were collected by centrifugation and kept on ice during all
staining and wash steps. After washing twice in PBS containing 1%
FBS, cells were fixed and permeabilized for 20 minutes with
Cytofix/Cytoperm Solution and washed twice more with Perm/
Wash Buffer (BD Biosciences). Perm/Wash Buffer was used for all
subsequent staining and wash steps. Permeabilized cells were
stained for intracellular Mer using a 1:75 dilution of anti-Mer
antibody (#1633-1, Epitomics) for 45 minutes, washed twice, and
incubated in a 1:200 dilution of DyLight549-labeled anti-rabbit
secondary antibody (Jackson ImmunoResearch) for 25 minutes.
After four washes, cells were resuspended in cold PBS, adhered to
poly-L-lysine–coated coverslips (BD Biosciences) for 10 minutes at
room temperature, and then affixed to glass slides with a drop of
mounting reagent (Prolong Antifade Gold with DAPI, Invitrogen).
Stained cells were visualized on a Zeiss LSM 510 META confocal
microscope and all images were processed using LSM image
browser software (Zeiss). Control experiments demonstrating
specificity of this antibody for Mer in immunofluorescence
imaging analyses are shown in Figure S3B.
Plasmid construction and transfection
Mer add-back DNA constructs were produced using standard
PCR methods. The coding region of Mer cDNA (Open
Biosystems) was amplified with HindIII and NotI restriction sites
and cloned into the pLNCX2 plasmid (Clontech). The kinase-
dead Mer mutant, K619R (MerKD), was produced using a
Mer Glycosylation & Nuclear Expression in Leukemia
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analogous DNA construct in pcDNA3 (Invitrogen), then sub-
cloned into pLNCX2. Constructs were sequenced to verify the
mutation and presence of the open reading frame.
Stable Jurkat add-back cell lines were developed using the
LRCX retroviral gene expression system (Clontech) and proce-
dures outlined in the Retrovirus Gene Transfer and Expression
User Manual. Briefly, GP2-293 packaging cells (Clontech) were
transfected with pVSV-G and either MerWT-pLNCX2, MerKD-
pLNCX2 or pLNCX2. Virus was collected at 48 and 72 hours
post-transfection, filtered and concentrated, and added to Mer-
knockdown Jurkat cells (constructed to stably express shRNA
vectors in WT Jurkat cells using the same methods and shRNA
constructs (Open Biosystems) as described previously for the 697
and REH human B-ALL cell lines [10]) in the presence of
polybrene (8 mg/ml ) for 18 hours. Selection began at 48 hours
post-transduction with 400 mg/ml G418.
Statistical analysis
Unless otherwise noted, all data are representative of three
independent experiments. Statistical significance of results, defined
by a P-value,0.05, was determined using Prism (Version 5;
GraphPad Software). Details regarding specific analyses are
indicated in the figure legends. Sequence motif analyses and
alignments were performed using ELM (eukaryotic linear motif)
resource [22] and Jalview software [49].
Supporting Information
Figure S1 Processes underlying Gas6-favored expres-
sion of the partial Mer glycoform. Human leukemia cell
lines were cultured for the indicated times in the presence of
200 nM Gas6 (+) or control (2), and Mer expression was detected
by western blot of whole-cell lysates. Blots were probed for
Tubulin to assess loading. (A) HPB-ALL cells were exposed to
Gas6 for 24 hours in media containing either 10% FBS or 0%
FBS. (B) 697 cells were exposed to a single dose of Gas6 and
collected after 48, 72, or 96 hours. Similar results were also
observed for Jurkat cells (not shown).
(TIF)
Figure S2 Gas6-induced expression of the partial Mer
glycoform does not require kinase activity. Jurkat cells
stably expressing a Mer add-back construct containing either wild
type (WT) or a kinase-dead (K619R) form of Mer were exposed to
200 nM Gas6 (+) or vehicle control (2) for the indicated times and
collected for western blot analysis of protein expression. (A)
Validation of kinase-inactivating mutation: Erk1/2 phosphoryla-
tion (p-Erk1/2), an indicator of Mer activation, is enhanced in cells
expressing WT, but not kinase-dead, Mer following a 10-minute
Gas6 stimulation. (B) Similar to the effects observed with WT
Mer, cells expressing kinase-dead Mer preferentially express the
partial Mer glycoform after an 18-hour exposure to 200 nM Gas6.
(TIF)
Figure S3 Both anti-Mer antibodies specifically recog-
nize the Mer receptor tyrosine kinase. All collection and
detection methods were performed as described in the ‘‘Materials
and Methods’’ section. (A) TAM receptor expression was detected
by western blot of whole-cell lysates collected from three human
cell lines—HeLa (cervical carcinoma), Jurkat (T-ALL), and NB4
(AML FAB M3). Each cell line displays a distinct pattern of TAM
receptor expression, indicated above in the western blot and below
in a summary table describing the presence (+) or absence (2)o f
each TAM receptor (grey shading represents lower expression
levels relative to other cell lines). These data demonstrate that the
anti-MerTK antibody (#1633-1, Epitomics) is specific for Mer
and does not cross-react with either of the other TAM receptors.
(B) The rabbit monoclonal anti-MerTK antibody (#1633-1,
Epitomics) displays similar specificity in immunofluorescence
staining. Left: Mer expression was determined by confocal imaging
of Jurkat cells stably expressing shRNA directed against GFP
(shControl, non-targeting control) or Mer (shMer1A) following
immunofluorescence staining for Mer, and WT Jurkat cells stained
only with secondary antibody (DyLight549) serve to demonstrate
lack of non-specific binding. Merged images of Mer (yellow) and
DAPI (blue) are shown and are representative of four independent
experiments. Right: Immunoblot detection of Mer in WT,
shControl, and shMer1A Jurkat cells (using the same anti-MerTK
antibody) serves as a reference for confocal images and
demonstrates sufficient shRNA-mediated knockdown of Mer. (C)
Surface expression of Mer was assessed by flow cytometry after
staining with the mouse monoclonal Mer590 antibody and
subsequent incubation with a PE-conjugated anti-mouse second-
ary antibody. Left: Surface Mer was measured in Jurkat cells stably
expressing either the shControl (red) or shMer1A (blue) construct,
and another set of shControl cells were incubated with isotype-
matched mouse IgG1 (grey) and then stained with secondary
antibody as a negative control. The decreased level of Mer signal
in shMer1A cells relative to shControl cells reflects a loss of
antibody labeling due to Mer-knockdown and demonstrates
specificity of the Mer590 antibody. Middle: A similar loss of
Mer590 antibody labeling is seen in HEK 293 cells—which also
express Tyro3, as well as Axl to a lesser extent, in addition to Mer
(western blot, right)—following stable shRNA-mediated Mer
knockdown relative to WT cells (immunoblot detection of Mer
in each cell line shown above flow cytometry histogram). Thus, the
loss of Mer590 labeling in Mer-knockdown HEK 293 cells, despite
the presence of other TAM receptors, further demonstrates
Mer590 antibody specificity for Mer.
(TIF)
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